標題: Titlebook: Analysis File of Drug-Induced Lung Injury; Expert Opinion for A Akihiko Gemma Book 2024 The Editor(s) (if applicable) and The Author(s), un [打印本頁] 作者: Fuctionary 時間: 2025-3-21 17:49
書目名稱Analysis File of Drug-Induced Lung Injury影響因子(影響力)
書目名稱Analysis File of Drug-Induced Lung Injury影響因子(影響力)學科排名
書目名稱Analysis File of Drug-Induced Lung Injury網絡公開度
書目名稱Analysis File of Drug-Induced Lung Injury網絡公開度學科排名
書目名稱Analysis File of Drug-Induced Lung Injury被引頻次
書目名稱Analysis File of Drug-Induced Lung Injury被引頻次學科排名
書目名稱Analysis File of Drug-Induced Lung Injury年度引用
書目名稱Analysis File of Drug-Induced Lung Injury年度引用學科排名
書目名稱Analysis File of Drug-Induced Lung Injury讀者反饋
書目名稱Analysis File of Drug-Induced Lung Injury讀者反饋學科排名
作者: Gratulate 時間: 2025-3-21 22:49
mTOR Inhibitors (Temsirolimus and Everolimus)st as anticancer drugs for renal cell cancer, and then, the indications with everolimus were expanded to cases of radically unresectable or metastatic neuroendocrine tumors, breast cancer, and nodular sclerosis.作者: RAG 時間: 2025-3-22 00:52
Antibody-Drug Conjugates (ADC) (Trastuzumab Emtansine and Trastuzumab Deruxtecan)cer and in 1 of 73 cases (1.4%) in a phase II study in Japan [1] (Fig. 9.1). An analysis (KATHERINE study) on the use of trastuzumab emtansine in postoperative adjuvant chemotherapy showed 21 cases (2.8%) of interstitial lung disease in 740 subjects, and the 11 cases were radiation pneumonitis [2] (作者: BARGE 時間: 2025-3-22 08:39 作者: 可行 時間: 2025-3-22 10:02 作者: 遺忘 時間: 2025-3-22 15:38
https://doi.org/10.1007/978-3-030-50726-8st as anticancer drugs for renal cell cancer, and then, the indications with everolimus were expanded to cases of radically unresectable or metastatic neuroendocrine tumors, breast cancer, and nodular sclerosis.作者: accomplishment 時間: 2025-3-22 18:15
https://doi.org/10.1007/978-3-030-60128-7cer and in 1 of 73 cases (1.4%) in a phase II study in Japan [1] (Fig. 9.1). An analysis (KATHERINE study) on the use of trastuzumab emtansine in postoperative adjuvant chemotherapy showed 21 cases (2.8%) of interstitial lung disease in 740 subjects, and the 11 cases were radiation pneumonitis [2] (作者: CIS 時間: 2025-3-22 22:46
Lecture Notes in Computer Sciencetrate, gemcitabine hydrochloride, and amrubicin hydrochloride (Table 10.1). The number of cases will be insufficient to understand low-frequency adverse drug reactions such as drug-induced lung injuries in a clinical trial, and usually, this information is confirmed in a post-marketing survey. Altho作者: ELUDE 時間: 2025-3-23 03:59 作者: 高調 時間: 2025-3-23 08:19 作者: Inferior 時間: 2025-3-23 11:26 作者: GNAW 時間: 2025-3-23 15:36
?pela Orehek,Gregor Petri?,Jan ?inigojAlthough the mechanism of onset of lung injuries induced by drugs has not been clearly identified, it has been generally accepted that the pathologic condition occurs through direct cellular damages or indirect ones by inflammatory reactions, an immunological mechanism, by drugs or their intermediate metabolites [1].作者: left-ventricle 時間: 2025-3-23 19:28 作者: eucalyptus 時間: 2025-3-23 22:56 作者: 親密 時間: 2025-3-24 02:35 作者: 套索 時間: 2025-3-24 10:07
HCI International 2020 - PostersAs a result of clinical studies, interstitial pneumonia is listed among important toxic events associated with the use of neoangiogenesis inhibitors. This information is included in the package insert. In this section, sunitinib, sorafenib, and bevacizumab, which were investigated in the post-marketing all-case survey are explained.作者: 樹木心 時間: 2025-3-24 12:05
Exposure Compensation from a Single ImageThe drug was used as an ALK inhibitor clinically at its first approval, and since then the indications have been expanded.作者: 狂怒 時間: 2025-3-24 15:50 作者: Antimicrobial 時間: 2025-3-24 19:39
Anti-EGFR Antibodies (Cetuximab, Panitumumab, and Necitumumab)Study period: September 2008–January 2009 [2, 3].作者: dilute 時間: 2025-3-25 02:57
Proteasome Inhibitor (Bortezomib)Bortezomib (Velcade) was approved for the production and sale on October 20, 2006, and was launched on December 1, 2006. At that time, this drug was placed as a specific medicine for multiple myeloma.作者: Aura231 時間: 2025-3-25 04:46 作者: REIGN 時間: 2025-3-25 09:52 作者: 懶惰民族 時間: 2025-3-25 14:52 作者: 易于 時間: 2025-3-25 18:52
Akihiko GemmaPresents abundant knowledge on event management of drug-induced lung disorders.In-depth analysis and interpretation of post-marketing surveillance data for various drugs causing pulmonary disorders.Un作者: 悶熱 時間: 2025-3-25 23:26 作者: 館長 時間: 2025-3-26 03:12
https://doi.org/10.1007/978-3-030-50726-8st as anticancer drugs for renal cell cancer, and then, the indications with everolimus were expanded to cases of radically unresectable or metastatic neuroendocrine tumors, breast cancer, and nodular sclerosis.作者: 招待 時間: 2025-3-26 06:59 作者: gout109 時間: 2025-3-26 11:13 作者: Mobile 時間: 2025-3-26 14:38
https://doi.org/10.1007/978-3-030-60128-7operative adjuvant chemotherapy showed 21 cases (2.8%) of interstitial lung disease in 740 subjects, and the 11 cases were radiation pneumonitis [2] (Fig. 9.2). In addition, it was reported that all 21 cases received radiation therapy. Compared to other ADCs, the frequency of drug-induced lung injuries was lower.作者: 暗諷 時間: 2025-3-26 18:44
Antibody-Drug Conjugates (ADC) (Trastuzumab Emtansine and Trastuzumab Deruxtecan)operative adjuvant chemotherapy showed 21 cases (2.8%) of interstitial lung disease in 740 subjects, and the 11 cases were radiation pneumonitis [2] (Fig. 9.2). In addition, it was reported that all 21 cases received radiation therapy. Compared to other ADCs, the frequency of drug-induced lung injuries was lower.作者: Communicate 時間: 2025-3-26 23:30
Lecture Notes in Computer Scienceugh post-marketing all-case surveys have recently been conducted for many molecular-targeted drugs in Japan, drugs which had been developed before were investigated in ordinary post-marketing surveys or were self-reported data.作者: interrupt 時間: 2025-3-27 04:48 作者: blackout 時間: 2025-3-27 08:48
Constantine Stephanidis,Margherita Antonability was not predictable. However, through this history, we have recognized the importance of informed consent about the efficacy, safety, and toxicities in developing subsequent medicinal products.作者: anthropologist 時間: 2025-3-27 10:56 作者: disciplined 時間: 2025-3-27 14:14 作者: PHONE 時間: 2025-3-27 20:44
Book 2024formation to provide a foundation for further research advancement. The book.?.offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies...?.作者: Synchronism 時間: 2025-3-28 00:23
8樓作者: 注視 時間: 2025-3-28 04:11
8樓作者: GREG 時間: 2025-3-28 10:19
9樓作者: 放肆的我 時間: 2025-3-28 11:58
9樓作者: 排名真古怪 時間: 2025-3-28 17:00
9樓作者: Aggregate 時間: 2025-3-28 19:58
9樓作者: 因無茶而冷淡 時間: 2025-3-29 00:35
10樓作者: Paleontology 時間: 2025-3-29 04:18
10樓作者: indenture 時間: 2025-3-29 08:32
10樓作者: figment 時間: 2025-3-29 11:42
10樓
